Did You Know?

Editor’s Picks

Latest News

Cancer Research UK and Dewpoint Therapeutics partner to advance potential first-in-class MYC condensate modulator into clinical development

DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer’s most important and historically undruggable...

ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline

TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix License supports...

Rapid Nutrition Announces SystemLS AI Mobile App to Accelerate International Growth and Create Recurring Subscription Revenue Opportunity

A key strategic initiative combining AI-powered personalised nutrition and fitness, Premium subscriptions and a phased rollout across key marketsLONDON, Nov....

Novartis Cosentyx® becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)

Cosentyx® (secukinumab) doubled sustained remission rates and demonstrated steroid-sparing effects vs placebo in Phase III trial¹Approval marks 11th US indication for Cosentyx,...

FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer

Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor...

error: Content is protected !!